Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


SCCA Clinical Studies: Phase I Program

 

PARP Inhibitor ABT-888 with Cisplatin and Vinorelbine (7161)
Phase I Study of ABT-888 (Veliparib) in Combination With Cisplatin and Vinorelbine (Navelbine) for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer

Investigator: Eve Rodler, MD;   Conditions: Advanced Breast Cancer;    Status: Closed;   Study ID: NCT01104259

PF-05082566 (4-1BB agonist mAb) for Advanced Cancer or B-Cell Lymphoma (UW10051)
A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma (NHL)

Investigator: Ajay K. Gopal, MD;   Conditions: Non-Hodgkin's Lymphoma (NHL);    Status: Recruiting;   Study ID: NCT01307267

GA101 (RO5072759) for Previously Untreated Chronic Lymphocytic Leukemia (2514)
An Open-Label, Multicenter, Phase Ib Trial of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Investigator: Ajay K. Gopal, MD;   Conditions: Chronic Lymphocytic Leukemia;    Status: Closed;   Study ID: NCT01300247

LY2157299 for Metastatic Cancer and Advanced or Metastatic Pancreatic Cancer
A Phase 1b/2 Study With Gemcitabine and LY2157299 for Patients With Metastatic Cancer (Phase 1b) and Advanced or Metastatic Unresectable Pancreatic Cancer (Phase 2)

Investigator: Andrew Coveler, MD;   Conditions: Neoplasms, Neoplasm Metastasis, Pancreatic Cancer;    Status: Closed;   Study ID: NCT01373164

Dose-Escalation Study of MLN9708 (C16001) (UW08039)
An Open-Label, Dose Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies

Investigator: John Thompson, MD;   Conditions: Advanced Non-Hematologic Malignancies, Non Small Cell Lung Cancer, Head and Neck Cancer, Soft Tissue Sarcoma, Prostate Cancer;    Status: Closed;   Study ID: NCT00830869

SGN-75 + Everolimus for Metastatic Renal Cell Carcinoma
A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma

Investigator: John A. Thompson, MD;   Conditions: Renal Cell Carcinoma;    Status: Closed;   Study ID: NCT01677390

Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-Small Cell Lung Cancer, or Head and Neck Cancer
A Phase 1 Study of Recombinant Human IL15 (rhIL15) in Adults With Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Head and Neck Cancer

Investigator: John A. Thompson, MD;   Conditions: Melanoma, Kidney Cancer, Non-Small Cell Lung Cancer, Head and Neck Cancer;    Status: Closed;   Study ID: NCT01727076

PEGPH20 for Stage IV Untreated Pancreatic Cancer (2687)
A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase)Combined With Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer

Investigator: Sunil R. Hingorani, MD;   Conditions: Metastatic Pancreatic Cancer;    Status: Recruiting;   Study ID: NCT01839487

SGN-LIV1A for Breast Cancer (13038)
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With LIV-1-Positive Metastatic Breast Cancer

Investigator: Jennifer M. Specht, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01969643

MPDL3280A + Cobimetinib for Locally Advanced or Metastatic Cancer
A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors

Investigator: Laura Chow, MD;   Conditions: Neoplasms;    Status: Closed;   Study ID: NCT01988896

BMS-986016 for Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas (13045)
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 (BMS-986016) in Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas

Investigator: Ajay K. Gopal, MD;   Conditions: Hematologic Neoplasms;    Status: Pending;   Study ID: NCT02061761

MK-3475 + PegIFN-2b and MK-3475 + Ipilimumab
A Phase I/II Clinical Trial to Study the Safety and Tolerability of MK-3475 + Pegylated Interferon Alfa-2b (PEG-IFN) and MK-3475 + Ipilimumab (IPI) in Subjects With Advanced Melanoma (MEL) and Renal Cell Carcinoma (RCC)

Investigator: John Thompson, MD;   Conditions: Renal Cell Carcinoma, Melanoma;    Status: Recruiting;   Study ID: NCT02089685

ID-LV305 for Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1
A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1

Investigator: Seth M. Pollack, MD;   Conditions: Breast Cancer, Melanoma, Non-small Cell Lung Cancer, Ovarian Cancer, Sarcoma;    Status: Recruiting;   Study ID: NCT02122861

MEDI0680 (AMP-514) With MEDI4736 for Advanced Malignancies
A Phase 1, Open-label Study to Evaluate the Safety and Tolerability of MEDI0680 (AMP-514) in Combination With MEDI4736 in Subjects With Advanced Malignancies

Investigator: Laura Chow, MD ;   Conditions: Advanced Malignancies;    Status: Closed;   Study ID: NCT02118337

PF-06664178 for Advanced Solid Tumors
A Phase 1, Dose Escalation Study Of PF-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors

Investigator: Keith Eaton, MD;   Conditions: Neoplasms;    Status: Recruiting;   Study ID: NCT02122146

ME-344 in Combination With Hycamtin® for Solid Tumors
A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination With Topotecan (Hycamtin®) in Patients With Solid Tumors

Investigator: Barbara A. Goff, MD;   Conditions: Solid Tumors;    Status: Recruiting;   Study ID: NCT02100007

PF-05082566 Plus MK-3475 for Advanced Solid Tumors
A Phase 1 Study Of The 4-1BB Agonist PF-05082566 In Combination With The PD-1 Inhibitor MK-3475 In Patients With Advanced Solid Tumors

Investigator: Laura Q.M. Chow, MD;   Conditions: Advanced Solid Tumors;    Status: Recruiting;   Study ID: NCT02179918